Submitted by Anonymous (not verified) on 6 October 2025 - 16:06
Human medicines European public assessment report (EPAR): Nuvaxovid, COVID-19 Vaccine (recombinant, adjuvanted), Date of authorisation: 20/12/2021, Revision: 21, Status: Authorised
Source: